ClinicalTrials.govpublic full text
Safety, Tolerability and Pharmacokinetics of a Monoclonal Antibody Specific to B-and T-Lymphocyte Attenuator (BTLA) as Monotherapy and in Combination With an Anti-PD1 Monoclonal Antibody for Injection in Subjects With Advanced Malignancies
advanced unresectable solid tumor, metastatic solid tumor
This document is indexed with metadata only — full text is not available in the archive for this record.
Open the official source ↗
Record · ID 442107
Retrieved via
Conceptio — every document is proof-bundled with source, license, and retrieval metadata.